Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety w wieku 45 lat lub starsze z nieprawidłowym krwawieniem z dróg rodnych lub po menopauzie.
- •Kobiety w wieku 18-44 lat z nieprawidłowym krwawieniem i jednym czynnikiem ryzyka raka trzonu macicy (otyłość, PCOS, stosowanie tamoksyfenu).
- •Kobiety w wieku 18 lat lub starsze z potwierdzonym rakiem trzonu macicy (przed planowaną operacją).
- •Kobiety z potwierdzoną atypową hiperplazją błony śluzowej macicy (przed planowaną operacją).
✗ Disqualifies
- •Wcześniejsze usunięcie macicy.
- •Ciąża.
- •Wcześniejsze napromieniowanie miednicy lub pochwy.
- •Nowotwór w ciągu ostatnich 5 lat (z wyjątkiem raka skóry - podstawnokomórkowego).
- •Chemioterapia w ciągu ostatnich 5 lat.
- •Obecny rak szyjki macicy, pochwy, sromu lub zmiany przednowotworowe.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 29, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (25)
Mayo Clinic
Phoenix, United States
Mayo Clinic
Jacksonville, United States
My GYN Care
Miami, United States
Genoma Research, Inc.
Miami, United States
Orlando Health
Orlando, United States
Signature Women's Healthcare, LLC
Pembroke Pines, United States
Sarasota Memorial Health Care System
Sarasota, United States
Piedmont Healthcare
Atlanta, United States
University of Chicago
Chicago, United States
Providea Health Partners, LLC
Evergreen Park, United States
Ochsner Clinic Foundation
New Orleans, United States
Henry Ford Health
Detroit, United States
Valley OB-GYN Clinic
Saginaw, United States
Mayo Clinic
Rochester, United States
University of Mississippi Medical Center
Jackson, United States
The Woman's Health Pavilion
Howard Beach, United States
The Woman's Health Pavilion
Westbury, United States
Altru Health System
Grand Forks, United States
Cleveland Clinic
Cleveland, United States
Total Women's Care of the Heights
Houston, United States
Medical Colleagues of Texas, LLP
Katy, United States
Virginia Commonwealth University/ Massey Cancer Center
Richmond, United States
Mayo Clinic Health System - Northwest Wisconsin
Eau Claire, United States
Mayo Clinic Health System - Southwest Wisconsin
La Crosse, United States
Medical College of Wisconsin
Milwaukee, United States
Trial contact
Maureen A Lemens, BSN
Clinical Trials Referral Office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/30/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.